New UK Study Confirms: Alpha-Stim Improves Quality of Life By Relieving Anxiety

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”true” min_height=”” hover_type=”none” link=”” border_sizes_top=”” border_sizes_bottom=”” border_sizes_left=”” border_sizes_right=”” first=”true”][fusion_text]Researchers from the United Kingdom’s Northamptonshire Healthcare NHS Foundation Trust (NHFT) and General Practice Alliance (GPA) recently conducted a study to examine whether Alpha-Stim® can be a useful tool to improve quality of life for those with anxiety and depression.

The Alpha-Stim AID
Alpha-Stim is a CES device that delivers a microcurrent of electricity to balance the user’s brainwaves

Currently in the UK, psychological intervention is a recommended treatment for GAD, but patients face long wait times for appointments, individual therapy can be expensive, and has non-response rates of 60-66%.¹ Medications are another standard option, but these come with the risk of unpleasant side effects, are not always effective, and can be costly.

With these downfalls to psychotherapy and medications as first-line treatments, the NHFT and GPA researchers sought to analyze the effectiveness of Alpha-Stim as an alternative treatment option. Alpha-Stim is a cranial electrotherapy stimulation (CES) device that delivers a microcurrent of electricity, through earclip electrodes, to balance the user’s brainwaves. The patented waveform of electricity is painless, and the device is compact and easy to use in a patient’s own home. Treatments take just 20 minutes per day and a physician’s supervision is not required.

While more than 140 clinical research studies have already proven the safety and effectiveness of Alpha-Stim at treating anxiety and depression – including one by the NHS itself that proved the clinical- and cost-effectiveness of the device at treating GAD – this new study went one step further, in an attempt to determine the device’s impact on quality of life itself.

After 6 weeks of treatment with Alpha-Stim, improvements in anxiety and depression were on par with previous studies, which was no surprise to researchers. What was unique to this study, however, was the concrete evidence of an improved quality of life: “Of these improvements the dimensions of self-care, ability to perform usual activities and anxiety/depression were statistically significant. The largest effect sizes were observed in ability to perform usual activities and the anxiety/depression dimension. This indicates the positive impact of Alpha-Stim on the real-world functioning and wellbeing of patients.”²

Feet standing on a drawing of a happy face.
Alpha-Stim lifts the burden of anxiety and depression so effectively that people can live their lives the way they want to.

In other words, Alpha-Stim lifts the burden of anxiety and depression so effectively that people can genuinely live their lives the way they want to. With medications, you may find relief from anxiety and depression but with the cost of unpleasant side effects that drag you down. Therapy may provide some benefit to some people, but you may have to wait weeks or even months for a session. With Alpha-Stim, you can conduct a treatment whenever it is convenient for you, in the comfort of your own home – without investing the time in traveling to and from a therapy session, and without the risk of lasting side effects from medications.

Why settle for a treatment option that is anything less than ideal? When you struggle with anxiety and depression, you want relief from your symptoms without accepting some other detriment such as lost time, a large financial burden, or unpleasant side effects. Alpha-Stim lets you have the best of all worlds. With Alpha-Stim, you get relief from your anxiety and depression, as well as an overall improved quality of life. Patients have said so for decades, and now the research does, too.

The abstract of this study is available; the full text of the study is here.

About Alpha-Stim®

Alpha-Stim is an FDA cleared, handheld medical device that has been proven time and again to effectively treat acute, post-traumatic, and chronic pain, as well as anxiety, insomnia, and depression. Alpha-Stim uses cranial electrotherapy stimulation (CES), delivered through a patented waveform via two earclip electrodes, to treat anxiety, insomnia, and depression. Microcurrent electrical therapy (MET) delivers pain relief directly to the source of discomfort via two handheld Smart Probes.

The safety and effectiveness of Alpha-Stim is backed by over 140 independent clinical research studies. Unlike with medications, there is no risk of addiction or lasting side effects.

Alpha-Stim is available by prescription in the United States and over-the-counter in other countries. Get started today!

See minor and self-limiting risks >

¹Griffiths, C., Leathlean, C., Smart, D., Zafar, A., Hall, C.-L. and Deeks, S. (2021) Alpha-Stim Cranial Electrotherapy Stimulation (CES) for Anxiety Treatment: Outcomes in a United Kingdom (UK) Primary Care Practice. Open Journal of Psychiatry, 11, 187
²Griffiths, C., et al., 196
    Your Cart
    Your cart is emptyReturn to Shop